Biomarkers over Time: From Visual Contrast Sensitivity to Transcriptomics in Differentiating Chronic Inflammatory Response Syndrome and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. — CFSMEATLAS
Biomarkers over Time: From Visual Contrast Sensitivity to Transcriptomics in Differentiating Chronic Inflammatory Response Syndrome and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
Dooley, Ming · International journal of molecular sciences · 2025 · DOI
Quick Summary
This review examines how doctors can better distinguish between two similar-looking illnesses: Chronic Inflammatory Response Syndrome (CIRS) and ME/CFS. The authors trace how testing methods have evolved from simple vision tests to advanced blood tests that read genetic activity. They suggest that some patients diagnosed with ME/CFS may actually have CIRS, which is treatable if properly identified.
Why It Matters
Accurate differentiation between CIRS and ME/CFS could improve treatment outcomes, as these conditions may require different therapeutic approaches. Many patients may be misdiagnosed, delaying appropriate care. Better biomarker frameworks could reduce diagnostic uncertainty and help clinicians tailor interventions to the underlying pathophysiology.
Observed Findings
Visual contrast sensitivity testing evolved as an early functional biomarker for environmental illness assessment
Transcriptomic profiling via GENIE platform can classify disease stages and differentiate CIRS from other fatiguing illnesses
Both CIRS and ME/CFS demonstrate immune dysregulation, mitochondrial impairment, and vascular dysfunction
CIRS biomarker framework shows greater reproducibility and clarity than current ME/CFS diagnostic criteria
Biomarker development in CIRS has progressed systematically over 20+ years from functional to molecular assessment
Inferred Conclusions
A chronological, layered biomarker approach improves diagnostic accuracy in complex chronic illness
ME/CFS research lacks the unified diagnostic and biomarker validation framework established in CIRS
Some patients with ME/CFS diagnoses may represent unrecognized CIRS cases with environmental exposure links
Structured biomarker timelines are essential for differential diagnosis and guiding targeted treatment
Remaining Questions
Can transcriptomic biomarkers reliably and prospectively distinguish CIRS from ME/CFS in diverse patient populations?
What This Study Does Not Prove
This review does not prove that biomarkers definitively distinguish CIRS from ME/CFS in all patients, nor does it establish that current ME/CFS diagnoses are wrong. It presents a framework comparison rather than original validation data. The claim that some ME/CFS cases are 'actually CIRS' is based on overlapping features, not definitive causal evidence.